Krystal Biotech Stock
Krystal Biotech Stock
A loss of -1.040% shows a downward development for Krystal Biotech.
Krystal Biotech is currently one of the favorites of our community with 16 Buy predictions and no Sell predictions.
With a target price of 173 € there is a slightly positive potential of 17.65% for Krystal Biotech compared to the current price of 147.05 €.
So far the community has only identified positive things for Krystal Biotech stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Krystal Biotech in the next few years
Pros
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Krystal Biotech vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Krystal Biotech | -1.040% | -7.154% | -4.744% | 92.987% | 28.103% | - | - |
| Ardelyx Inc. | 0.910% | -2.116% | -15.296% | 40.514% | 4.048% | -12.204% | - |
| Salarius Pharmaceuticals Inc. | -3.170% | 2.315% | -15.000% | -67.971% | -20.360% | -98.187% | -99.994% |
| Brainstorm Cell | 1.170% | -1.874% | -1.485% | -81.975% | 114.440% | -80.717% | - |
Comments
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock.
Show more
Ratings data for KRYS provided by MarketBeat
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $204.00 price target on the stock, up previously from $178.00.
Show more
Ratings data for KRYS provided by MarketBeat
Krystal Biotech, Inc. (NASDAQ: KRYS) had its price target raised by analysts at Citigroup Inc. from $160.00 to $195.00. They now have a "buy" rating on the stock.
Show more
Ratings data for KRYS provided by MarketBeat